Signals, Powered By EquityPandit
Sun Pharmaceuticals Industries subsidiary receives nod from the US health regulator to market generic version of GSK’s Coreg CR,extended release capsules in the American market.
Sun Pharma stated that, one of the its wholly-owned subsidiaries has received final approval from US Food and Drug Administration (USFDA) for the generic product in strengths of 10mg, 20mg, 40mg and 80 mg.
Coreg CR extended release capsules are suggested for treating various heart conditions, including heart failure and high blood pressure.
